Primus Pharms patents expiration
1. Impoyz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10064875 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US10588914 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9956231 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9855334 | PRIMUS PHARMS | Topical compositions comprising a corticosteroid |
Mar, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 28, 2020 |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: Twice daily topical treatment of moderate to severe plaque psoriasis.; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older; Plaque psoriasis
Dosage: CREAM;TOPICAL
IMPOYZ family patents
2. Metaxalone patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11918559 | PRIMUS PHARMS | Reduced dose metaxalone formulations |
Jul, 2039
(15 years from now) | |
Drugs and Companies using METAXALONE ingredient
Market Authorisation Date: 01 June, 2015
Treatment: NA
Dosage: TABLET;ORAL
METAXALONE family patents
3. Sernivo patents
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9775851 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9364485 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9655907 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US10179137 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9433630 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9877974 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9439911 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 05, 2019 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 05 February, 2016
Treatment: Treatment of plaque psoriasis
Dosage: SPRAY;TOPICAL
SERNIVO family patents